Rindopepimut

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine[1] which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.[2]

The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope[3]) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).[4]

The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.[3]

Clinical trials

Glioblastoma

The phase II ACT III study reported encouraging results in June 2015.[1]

The ReACT clinical trial for glioblastoma reported encouraging results in 2015.[2]

In March 2016 the phase III ACT IV trial [5] was terminated because it did not increase overall survival.[6]

References

  1. 1 2 Zussman; et al. (2015). "Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma.". doi:10.1227/01.neu.0000465855.63458.0c.
  2. 1 2 Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows. WSJ Nov 2015
  3. 1 2 FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma. Feb 2015
  4. ↑ rindopepimut definition
  5. ↑ Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)
  6. ↑ Rindopepimut Misses OS Endpoint in Phase III Glioblastoma Trial. March 2016

See also

This article is issued from Wikipedia - version of the 6/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.